公开(公告)号：US12186276B2

公开(公告)日：2025-01-07

申请号：US17727255

申请日：2022-04-22

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Colette Song ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K39/00 ,  A61K35/17 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/705 ,  C07K14/71 ,  C07K14/72 ,  C07K14/725 ,  C07K14/81 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K16/38 ,  C07K16/40 ,  C12N5/0783 ,  C12N9/02 ,  C12N9/12 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G16B25/00 ,  G16B25/10 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12180259B2

公开(公告)日：2024-12-31

申请号：US17587474

申请日：2022-01-28

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Phillip Mueller ,  Julia Leibold ,  Valentina Goldfinger

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  C12N5/0784 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12168043B2

公开(公告)日：2024-12-17

申请号：US17727244

申请日：2022-04-22

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Colette Song ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K38/00 ,  A61K39/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/705 ,  C07K14/71 ,  C07K14/72 ,  C07K14/725 ,  C07K14/81 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K16/38 ,  C07K16/40 ,  C12N5/0783 ,  C12N9/02 ,  C12N9/12 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G16B25/00 ,  G16B25/10 ,  A61K35/17

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12144852B2

公开(公告)日：2024-11-19

申请号：US17587536

申请日：2022-01-28

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Phillip Mueller ,  Julia Leibold ,  Valentina Goldfinger

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12097249B2

公开(公告)日：2024-09-24

申请号：US17581049

申请日：2022-01-21

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Phillip Mueller ,  Julia Leibold ,  Valentina Goldfinger

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68 ,  A61K38/00

CPC classification number: A61K39/0011 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/30 ,  C12N5/0636 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/5748 ,  G01N33/6848 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K2319/00 ,  C12N2310/16 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57407 ,  G01N2570/00 ,  G01N2800/52

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12036271B2

公开(公告)日：2024-07-16

申请号：US17838017

申请日：2022-06-10

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Anita Wiebe ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K38/08 ,  A61K35/17 ,  A61K39/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00 ,  C07K14/74 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/115

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/08 ,  C07K7/06 ,  C07K7/08 ,  C07K14/001 ,  C07K14/70539 ,  C07K16/2833 ,  C12N5/0638 ,  C12N15/115 ,  A61K2039/5158 ,  C07K2319/00 ,  C12N2310/16 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/51 ,  C12N2501/515

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12023372B2

公开(公告)日：2024-07-02

申请号：US17675492

申请日：2022-02-18

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K39/00 ,  A61P35/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574

CPC classification number: A61K39/0011 ,  A61P35/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/4748 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2833 ,  C07K16/3076 ,  C12N5/0636 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/57492 ,  A61K39/00 ,  A61K2039/5158 ,  C07K2319/40 ,  C12N2310/16 ,  C12N2501/50 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N2333/70539

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12018064B2

公开(公告)日：2024-06-25

申请号：US17396305

申请日：2021-08-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Lea Stevermann

IPC: A61K38/00 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/00 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N9/64 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/566 ,  G01N33/569

CPC classification number: C07K14/70539 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12Q1/6886 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12006349B2

公开(公告)日：2024-06-11

申请号：US17396323

申请日：2021-08-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Lea Stevermann

IPC: A61K38/00 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/00 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N9/64 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/566 ,  G01N33/569

CPC classification number: C07K14/70539 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12Q1/6886 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US11957742B2

公开(公告)日：2024-04-16

申请号：US18158604

申请日：2023-01-24

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K39/00 ,  A61P35/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574

CPC classification number: A61K39/0011 ,  A61P35/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/4748 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2833 ,  C07K16/3076 ,  C12N5/0636 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/57492 ,  A61K39/00 ,  A61K2039/5158 ,  C07K2319/40 ,  C12N2310/16 ,  C12N2501/50 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N2333/70539

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.